x
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
o
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
Massachusetts
|
04-3145961
|
(State or Other Jurisdiction of
|
(I.R.S. Employer Identification No.)
|
Incorporation or Organization)
|
|
32 Wiggins Avenue, Bedford, Massachusetts
|
01730
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
Large accelerated filer
o
|
Accelerated filer
x
|
Non-accelerated filer
o
(Do not check if a smaller
reporting company)
|
Smaller reporting
company
o
|
Anika Therapeutics, Inc. and Subsidiaries
|
Consolidated Balance Sheets
|
(unaudited)
|
ASSETS
|
March 31,
2014
|
December 31,
2013
|
||||||
Current assets: | ||||||||
Cash and cash equivalents
|
$ | 82,160,251 | $ | 63,333,160 | ||||
Accounts receivable, net of reserves of $592,420 and $593,023 at March 31, 2014 and December 31, 2013, respectively
|
16,466,436 | 18,736,845 | ||||||
Inventories
|
12,981,495 | 10,996,785 | ||||||
Current portion deferred income taxes
|
659,040 | 659,040 | ||||||
Prepaid expenses and other
|
1,217,403 | 865,957 | ||||||
Total current assets
|
113,484,625 | 94,591,787 | ||||||
Property and equipment, at cost | 52,768,367 | 52,413,423 | ||||||
Less: accumulated depreciation | (20,134,401 | ) | (19,474,712 | ) | ||||
32,633,966 | 32,938,711 | |||||||
Long-term deposits and other | 69,080 | 69,080 | ||||||
Intangible assets, net | 18,439,286 | 18,998,409 | ||||||
Goodwill | 9,434,289 | 9,443,894 | ||||||
Total Assets | $ | 174,061,246 | $ | 156,041,881 | ||||
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
||||||||
Current liabilities: | ||||||||
Accounts payable
|
$ | 2,742,808 | $ | 2,793,911 | ||||
Accrued expenses
|
4,497,706 | 5,537,881 | ||||||
Deferred revenue
|
46,412 | 180,433 | ||||||
Income taxes payable
|
424,993 | 770,276 | ||||||
Total current liabilities
|
7,711,919 | 9,282,501 | ||||||
Other long-term liabilities | 1,089,708 | 1,133,544 | ||||||
Long-term deferred revenue | 72,367 | 2,054,941 | ||||||
Deferred tax liability | 8,617,245 | 7,936,864 | ||||||
Commitments and contingencies (Note 9) | ||||||||
Stockholders’ equity: | ||||||||
Preferred stock, $.01 par value; 1,250,000 shares authorized, no shares issued and outstanding at March 31, 2014 and December 31, 2013, respectively
|
- | - | ||||||
Common stock, $.01 par value; 30,000,000 shares authorized, 14,620,032 and 14,289,308 shares issued and outstanding at March 31, 2014 and December 31, 2013, respectively
|
146,200 | 142,893 | ||||||
Additional paid-in-capital
|
76,534,563 | 70,606,031 | ||||||
Accumulated currency translation adjustment
|
(1,725,211 | ) | (1,699,095 | ) | ||||
Retained earnings
|
81,614,455 | 66,584,202 | ||||||
Total stockholders’ equity
|
156,570,007 | 135,634,031 | ||||||
Total Liabilities and Stockholders’ Equity | $ | 174,061,246 | $ | 156,041,881 |
Anika Therapeutics, Inc. and Subsidiaries
Condensed Consolidated Statements of Operations and Comprehensive Income
(unaudited)
|
Three Months Ended March 31,
|
||||||||
2014
|
2013
|
|||||||
Product revenue
|
$ | 14,351,405 | $ | 14,494,489 | ||||
Licensing, milestone and contract revenue
|
19,658,882 | 752,522 | ||||||
Total revenue
|
34,010,287 | 15,247,011 | ||||||
Operating expenses:
|
||||||||
Cost of product revenue
|
4,361,019 | 4,841,170 | ||||||
Research & development
|
2,287,715 | 1,582,910 | ||||||
Selling, general & administrative
|
3,490,985 | 3,947,114 | ||||||
Restructuring credits
|
- | (135,607 | ) | |||||
Total operating expenses
|
10,139,719 | 10,235,587 | ||||||
Income from operations
|
23,870,568 | 5,011,424 | ||||||
Interest income (expense), net
|
467 | (39,558 | ) | |||||
Income before income taxes
|
23,871,035 | 4,971,866 | ||||||
Provision for income taxes
|
8,840,782 | 1,903,864 | ||||||
Net income
|
$ | 15,030,253 | $ | 3,068,002 | ||||
Basic net income per share:
|
||||||||
Net income
|
$ | 1.04 | $ | 0.23 | ||||
Basic weighted average common shares outstanding
|
14,461,367 | 13,406,952 | ||||||
Diluted net income per share:
|
||||||||
Net income
|
$ | 0.97 | $ | 0.21 | ||||
Diluted weighted average common shares outstanding
|
15,499,447 | 14,357,110 | ||||||
Net income | $ | 15,030,253 | $ | 3,068,002 | ||||
Other comprehensive income | ||||||||
Foreign currency translation adjustment
|
(26,116 | ) | (749,450 | ) | ||||
Comprehensive income | $ | 15,004,137 | $ | 2,318,552 |
Anika Therapeutics, Inc. and Subsidiaries
Condensed Consolidated Statements of Cash Flows
(unaudited)
|
Three Months Ended March 31,
|
||||||||
2014
|
2013
|
|||||||
Cash flows from operating activities: | ||||||||
Net income
|
$ | 15,030,253 | $ | 3,068,002 | ||||
Adjustments to reconcile net income to net cash provided by operating activities:
|
||||||||
Depreciation and amortization
|
1,198,799 | 1,202,208 | ||||||
Stock-based compensation expense
|
427,823 | 422,959 | ||||||
Deferred income taxes
|
(323,669 | ) | (139,747 | ) | ||||
Provision for inventory
|
31,778 | 258,195 | ||||||
Tax benefit from exercise of stock options
|
(4,436,249 | ) | (64,642 | ) | ||||
Changes in operating assets and liabilities:
|
||||||||
Accounts receivable
|
2,140,848 | 6,373,839 | ||||||
Inventories
|
(2,016,631 | ) | (1,969,179 | ) | ||||
Prepaid expenses, other current and long-term assets
|
(345,415 | ) | 705,078 | |||||
Long-term deposits and other
|
- | 8,499 | ||||||
Accounts payable
|
51,712 | 1,354,318 | ||||||
Accrued expenses
|
(1,104,945 | ) | (2,351,133 | ) | ||||
Deferred revenue
|
(2,113,086 | ) | (725,067 | ) | ||||
Income taxes payable
|
5,099,027 | (1,834,739 | ) | |||||
Other long-term liabilities
|
(43,588 | ) | (239,737 | ) | ||||
Net cash provided by operating activities
|
13,596,657 | 6,068,854 | ||||||
Cash flows from investing activities:
|
||||||||
Proceeds from sale of assets
|
- | 135,607 | ||||||
Purchase of property and equipment
|
(276,513 | ) | (35,802 | ) | ||||
Net cash provided by (used in) investing activities
|
(276,513 | ) | 99,805 | |||||
Cash flows from financing activities:
|
||||||||
Principal payments on debt
|
- | (400,000 | ) | |||||
Proceeds from exercise of stock options
|
1,067,767 | 1,097,016 | ||||||
Tax benefit from exercise of stock options
|
4,436,249 | 64,642 | ||||||
Net cash provided by financing activities
|
5,504,016 | 761,658 | ||||||
Exchange rate impact on cash
|
2,931 | (32,228 | ) | |||||
Increase in cash and cash equivalents
|
18,827,091 | 6,898,089 | ||||||
Cash and cash equivalents at beginning of period
|
63,333,160 | 44,067,477 | ||||||
Cash and cash equivalents at end of period
|
$ | 82,160,251 | $ | 50,965,566 |
1.
|
Nature of Business
|
2.
|
Basis of Presentation
|
3.
|
Fair Value Measurements
|
|
•
|
Level 1 – Valuation is based upon quoted prices for identical instruments traded in active markets. Level 1 instruments include securities traded on active exchange markets, such as the New York Stock Exchange.
|
|
•
|
Level 2 – Valuation is based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant assumptions are observable in the market.
|
|
•
|
Level 3 – Valuation is generated from model-based techniques that use significant assumptions not observable in the market. These unobservable assumptions reflect our own estimates of assumptions market participants would use in pricing the asset or liability.
|
4.
|
Equity Incentive Plan
|
Three Months Ended
March 31,
|
||||||
2014
|
2013
|
|||||
Risk free interest rate
|
1.20% | - | 1.33% | 0.70% | ||
Expected volatility
|
53.28% | 57.60% | ||||
Expected lives (years)
|
4 | 4 | ||||
Expected dividend yield
|
0.00% | 0.00% |
5.
|
Earnings Per Share
|
Three months ended March 31,
|
||||||||
2014
|
2013
|
|||||||
Shares used in the calculation of basic earnings per share
|
14,461,367 | 13,406,952 | ||||||
Effect of dilutive securities:
|
||||||||
Stock options, SARs, and RSAs
|
1,038,080 | 950,158 | ||||||
Diluted shares used in the calculation of earnings per share
|
15,499,447 | 14,357,110 |
6.
|
Inventories
|
March 31,
2014
|
December 31,
2013
|
|||||||
Raw materials
|
$ | 6,109,938 | $ | 5,926,030 | ||||
Work-in-process
|
2,230,635 | 2,308,233 | ||||||
Finished goods
|
4,640,922 | 2,762,522 | ||||||
Total
|
$ | 12,981,495 | $ | 10,996,785 |
7.
|
Intangible Assets and Goodwill
|
March 31, 2014
|
December 31, 2013 | |||||||||||||||||||||||
Gross Value
|
Currency
Translation
Adjustment
|
Accumulated
Amortization
|
Net Book
Value
|
Net Book
Value
|
Useful Life
|
|||||||||||||||||||
Developed technology
|
$ | 16,700,000 | $ | (963,479 | ) | $ | (4,264,090 | ) | $ | 11,472,431 | $ | 11,753,003 | 15 | |||||||||||
In-process research & development
|
5,502,686 | (222,625 | ) | - | 5,280,061 | 5,286,127 |
Indefinite
|
|||||||||||||||||
Distributor relationships
|
4,700,000 | (424,265 | ) | (3,637,480 | ) | 638,255 | 863,655 | 5 | ||||||||||||||||
Patents
|
1,000,000 | (54,717 | ) | (241,456 | ) | 703,827 | 719,574 | 16 | ||||||||||||||||
Elevess trade name
|
1,000,000 | - | (655,288 | ) | 344,712 | 376,050 | 9 | |||||||||||||||||
Total
|
$ | 28,902,686 | $ | (1,665,086 | ) | $ | (8,798,314 | ) | $ | 18,439,286 | $ | 18,998,409 |
For the three
months ended
March 31,
2014
|
||||
Balance, beginning
|
$ | 9,443,894 | ||
Effect of foreign currency adjustments | (9,605 | ) | ||
Balance, ending | $ | 9,434,289 |
8.
|
Accrued Expenses
|
March 31,
2014
|
December 31,
2013
|
|||||||
Payroll and benefits
|
$ | 1,464,681 | $ | 2,728,616 | ||||
Clinical trial costs
|
1,259,914 | 882,651 | ||||||
Professional fees
|
321,445 | 383,231 | ||||||
Research grants
|
609,878 | 610,498 | ||||||
Restructuring costs
|
19,759 | 24,638 | ||||||
Other
|
822,029 | 908,247 | ||||||
Total
|
$ | 4,497,706 | $ | 5,537,881 |
9.
|
Commitments and Contingencies
|
10.
|
Deferred Revenue
|
11.
|
Income Taxes
|
12.
|
Segment and Geographic Information
|
Three Months Ended March 31,
|
||||||||||||||||
2014
|
2013
|
|||||||||||||||
Revenue
|
Percentage of
Revenue
|
Revenue
|
Percentage of
Revenue
|
|||||||||||||
Geographic Location:
|
||||||||||||||||
United States
|
$ | 31,533,817 | 93 | % | $ | 12,280,079 | 80 | % | ||||||||
Europe
|
1,695,816 | 5 | % | 1,583,993 | 11 | % | ||||||||||
Other
|
780,654 | 2 | % | 1,382,939 | 9 | % | ||||||||||
Total revenue
|
$ | 34,010,287 | 100 | % | $ | 15,247,011 | 100 | % |
13.
|
Restructuring Credits
|
Restructuring Accrual
|
||||||||||||
Employee
Severance and
Related Benefits
|
Activity
Termination and
Facility Closure
Costs
|
Total
|
||||||||||
December 31, 2013
|
$ | 21,709 | $ | 2,929 | $ | 24,638 | ||||||
Cash Proceeds, Disbursements
|
(4,848 | ) | - | (4,848 | ) | |||||||
Foreign Exchange Impact
|
(28 | ) | (3 | ) | (31 | ) | ||||||
March 31, 2014
|
$ | 16,833 | $ | 2,926 | $ | 19,759 |
14.
|
Subsequent Event
|
ITEM 2.
|
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
|
·
|
Our future sales and product revenue, including geographic expansions, possible retroactive price adjustments, and expectations of unit volumes or other offsets to price reductions;
|
·
|
Our manufacturing capacity, efficiency gains and work-in-process manufacturing operations;
|
·
|
The timing, scope and rate of patient enrollment for clinical trials;
|
·
|
The development of possible line extensions and new products;
|
·
|
Our ability to achieve and/or maintain compliance with laws and regulations;
|
·
|
The timing of and/or receipt of Food and Drug Administration (“FDA”), foreign or other regulatory approvals, clearances, and/or reimbursement approvals of current, new or potential products, and any limitations on such approvals;
|
·
|
Our intention to seek patent protection for our products and processes, and to protect our intellectual property;
|
·
|
Our ability to effectively compete against current and future competitors;
|
·
|
Negotiations with potential and existing partners, including our performance under any of our existing and future distribution, license or supply agreements, or our expectations with respect to sales and sales threshold milestones pursuant to such agreements;
|
·
|
The level of our revenue or sales in particular geographic areas and/or for particular products, and the market share for any of our products;
|
·
|
Our expectations of product revenue results in future quarters and for the full year 2014;
|
·
|
Our current strategy, including our corporate objectives, research and development activities and collaboration activities;
|
·
|
Our expectations regarding our joint health products, including existing products and expectations regarding new products, expanded uses of existing products, new distribution partnerships and revenue growth;
|
·
|
Our intention to increase our market share for joint health products in domestic and international markets or otherwise penetrate growing markets for osteoarthritis of the knee and other joints;
|
·
|
Our expectations regarding next generation osteoarthritis/joint health product development, clinical trials, regulatory approvals and commercial launches;
|
·
|
Our and Bausch & Lomb’s performance under the non-exclusive, three-year contract for the supply of AMVISC
®
and AMVISC
®
Plus ophthalmic viscoelastic products, and our expectations regarding revenue from ophthalmic products;
|
·
|
Our ability to commercialize AnikaVisc
TM
and AnikaVisc
TM
Plus and our expectations regarding such commercialization and the potential profits generated thereby;
|
·
|
Our ability to license our aesthetics product to new distribution partners domestically and outside the United States;
|
·
|
Our ability, and the ability of our distribution partners, to market our aesthetics dermatology product; and our expectations regarding the distribution and sales of our ELEVESS
TM
product and the timing thereof;
|
·
|
Our expectations regarding development of aesthetics product line extensions;
|
·
|
Our expectations regarding HYVISC
®
sales;
|
·
|
Our expectations regarding product gross margin;
|
·
|
Our expectations regarding CINGAL
TM
, including the expense associated therewith, and our ability to obtain regulatory approvals for this product;
|
·
|
Our expectation for changes in operating expenses, including research and development, and selling, general and administrative expenses;
|
·
|
The rate at which we use cash, the amounts used and generated by operations, and our expectations regarding the adequacy and usage of such cash;
|
·
|
Our expectation for capital expenditures spending and future amounts of interest income and expense;
|
·
|
Possible negotiations or re-negotiations with existing or new distribution or collaboration partners;
|
·
|
Our ability to continue streamlining operations and improving our manufacturing capabilities;
|
·
|
Our ability to obtain additional funds through equity or debt financings, strategic alliances with corporate partners and other sources, to the extent our current sources of funds are insufficient;
|
·
|
Our ability to manage and maintain the operations of Anika S.r.l. from one with losses, into a company generating continued profits;
|
·
|
The strength of the economies in which the Company operates or will operate, as well as the political stability of any of those geographic areas;
|
·
|
Our ability to effectively prioritize the many research and development projects underway;
|
·
|
Our ability to expand the therapeutic applications of our existing products and create new applications for our HA technology;
|
·
|
Our ability to obtain U.S. approval for orthopedic and other product franchises of Anika S.r.l., including the timing and potential success of such efforts, and to expand sales of these products in the U.S., including the impact such efforts may have on our revenue; and
|
·
|
Our ability to successfully defend the Company against lawsuits and claims, and the uncertain financial impact such lawsuits and claims and related defense costs may have on the Company.
|
Anika
|
Anika
S.r.l.
|
|
Orthobiologics
|
X
|
X
|
Dermal
Advanced wound care
Aesthetic dermatology
|
X
|
X
|
Surgical
Anti-adhesion
Ear, nose and throat care (“ENT”)
|
X
|
X
X
|
Ophthalmic
|
X
|
|
Veterinary
|
X
|
Three Months Ended March 31, 2014 Compared to the Three Months Ended March 31, 2013
|
||||||||||||
2014
|
2013
|
Inc/(Dec)
|
||||||||||
Product revenue
|
$ | 14,351,405 | $ | 14,494,489 | (1 | %) | ||||||
Licensing, milestone and contract revenue
|
19,658,882 | 752,522 | 2512 | % | ||||||||
Total revenue
|
34,010,287 | 15,247,011 | 123 | % | ||||||||
Operating expenses:
|
||||||||||||
Cost of product revenue
|
4,361,019 | 4,841,170 | (10 | %) | ||||||||
Research & development
|
2,287,715 | 1,582,910 | 45 | % | ||||||||
Selling, general & administrative
|
3,490,985 | 3,947,114 | (12 | %) | ||||||||
Restructuring credits
|
- | (135,607 | ) | N/M | ||||||||
Total operating expenses
|
10,139,719 | 10,235,587 | (1 | %) | ||||||||
Income from operations
|
23,870,568 | 5,011,424 | 376 | % | ||||||||
Interest income (expense), net
|
467 | (39,558 | ) | (101 | %) | |||||||
Income before income taxes
|
23,871,035 | 4,971,866 | 380 | % | ||||||||
Provision for income taxes
|
8,840,782 | 1,903,864 | 364 | % | ||||||||
Net income
|
$ | 15,030,253 | $ | 3,068,002 | 390 | % | ||||||
Product gross profit
|
$ | 9,990,386 | $ | 9,653,319 | 3 | % | ||||||
Product gross margin
|
70 | % | 67 | % |
Three Months Ended March 31,
|
Increase (Decrease)
|
|||||||||||||||
2014
|
2013
|
$ | % | |||||||||||||
Orthobiologics
|
$ | 11,572,150 | $ | 11,283,547 | $ | 288,603 | 3 | % | ||||||||
Dermal
|
188,651 | 241,584 | (52,933 | ) | (22 | %) | ||||||||||
Surgical
|
1,752,020 | 988,864 | 763,156 | 77 | % | |||||||||||
Ophthalmic
|
208,584 | 928,458 | (719,874 | ) | (78 | %) | ||||||||||
Veterinary
|
630,000 | 1,052,036 | (422,036 | ) | (40 | %) | ||||||||||
$ | 14,351,405 | $ | 14,494,489 | $ | (143,084 | ) | (1 | %) |
ITEM 3.
|
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
|
Primary Market Risk Exposures
|
ITEM 4.
|
CONTROLS AND PROCEDURES
|
(a)
|
E
valuation of disclosure controls and procedures.
|
(b)
|
Changes in internal controls over financial reporting.
|
ITEM 1.
|
LEGAL PROCEEDINGS
|
ITEM 1A.
|
RISK FACTORS
|
ITEM 6.
|
EXHIBITS
|
*
|
Filed herewith
|
**
|
Furnished herewith.
|
ANIKA THERAPEUTICS, INC.
|
|||
Date: May 5, 2014
|
By:
|
/s/ SYLVIA CHEUNG
|
|
Sylvia Cheung
|
|||
Chief Financial Officer
|
|||
(Authorized Officer and Principal Financial Officer)
|
ANIKA THERAPEUTICS, INC. | |||
By: |
/s/ Charles H. Sherwood, Ph.D.
|
||
Its: |
President and Chief Executive Officer
|
||
EXECUTIVE | |||
/s/ Sylvia Cheung | |||
Sylvia Cheung |
To: | Anika Therapeutics, Inc. | |
From: | ||
Date: |
o | No inventions or improvements | ||
o | See below: | ||
o | Additional sheets attached | ||
The following is a list of all patents and patent applications in which I have been named as an inventor: | |||
o | None | ||
o | See below: | ||
ANIKA THERAPEUTICS, INC. | |||
BY:
|
/s/ Charles H. Sherwood, Ph.D.
|
||
President and Chief Executive Officer
|
|||
/s/ Sylvia Cheung
|
|||
Sylvia Cheung
|
1.
|
I have reviewed this report on Form 10-Q for the quarterly period ended March 31, 2014 of Anika Therapeutics, Inc.;
|
2.
|
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
3.
|
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
|
4.
|
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
|
(a)
|
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
(b)
|
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
(c)
|
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
|
(d)
|
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
|
5.
|
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
|
(a)
|
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
|
(b)
|
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
|
Date: May 5, 2014
|
/s/ CHARLES H. SHERWOOD
|
|
Charles H. Sherwood, Ph.D.
|
||
Chief Executive Officer
|
||
Principal Executive Officer
|
1.
|
I have reviewed this report on Form 10-Q for the quarterly period ended March 31, 2014 of Anika Therapeutics, Inc.;
|
2.
|
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
3.
|
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
|
4.
|
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
|
(a)
|
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
(b)
|
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
(c)
|
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
|
(d)
|
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
|
5.
|
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
|
(a)
|
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
|
(b)
|
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
|
Date: May 5, 2014
|
/s/ SYLVIA CHEUNG
|
|
Sylvia Cheung
|
||
Chief Financial Officer
|
||
Principal Financial Officer
|
Date: May 5, 2014
|
/s/ CHARLES H. SHERWOOD
|
|
Charles H. Sherwood, Ph.D.
|
||
Chief Executive Officer
|
||
Principal Executive Officer
|
||
Date: May 5, 2014
|
/s/ SYLVIA CHEUNG
|
|
Sylvia Cheung
|
||
Chief Financial Officer
|
||
Principal Financial Officer
|